Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S, Rolon-Steele D, Underiner TL, Weinberg LR, Worrell CS, Zeigler KS, Dorsey BD.

Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. doi: 10.1016/j.bmc.2011.09.006. Epub 2011 Sep 13.

PMID:
21967808
2.

2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.

Zificsak CA, Theroff JP, Aimone LD, Albom MS, Angeles TS, Brown RA, Galinis D, Grobelny JV, Herbertz T, Husten J, Kocsis LS, LoSardo C, Miknyoczki SJ, Murthy S, Rolon-Steele D, Underiner TL, Wells-Knecht KJ, Worrell CS, Zeigler KS, Dorsey BD.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):660-3. doi: 10.1016/j.bmcl.2010.12.013. Epub 2010 Dec 8.

PMID:
21190849
3.

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.

Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR.

Drug Metab Dispos. 2004 Feb;32(2):172-7.

PMID:
14744938
4.

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase.

Ward KW, Prokscht JW, Azzaranot LM, Mumawa JA, Roethke TJ, Stelman GJ, Walsh MJ, Zeigler KS, McSurdy-Freed JE, Kehlert JR, Chokshi J, Levy MA, Smith BR.

Xenobiotica. 2001 Nov;31(11):783-97.

PMID:
11765141

Supplemental Content

Loading ...
Support Center